Edesa Biotech, Inc. (NasdaqCM: EDSA)
Health Care · Biotechnology · CA
$2.57
-26.78% today · +6.2% 1Y
Edesa Biotech, Inc. (NasdaqCM: EDSA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $34.72M and employs 17 people.
Over the last twelve months the share price has gained 6.2%, trading between 0.72 and 20.32.
Tweenvest scores Edesa Biotech, Inc. across four factors: quality 37/100, value 77/100. Its strongest factor is value.
EDSA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $34.72M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.73
- Dividend yield
- —
- Beta (5Y)
- 1.22
- 52-week high
- $20.32
- 52-week low
- $0.72
- Avg volume (3M)
- —
- Shares outstanding
- 13.51M
- Employees
- 17
- Next earnings
- —
About Edesa Biotech, Inc.
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
- ISIN
- CA27966L3065
- Founded
- 2015
- Listed since
- Jun 21, 2010
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| NanoViricides, Inc.NYSEAM: NNVC | $35.22M | $1.38 | +6.15% |
| Elutia Inc.NasdaqCM: ELUT | $35.17M | $0.79 | -3.54% |
| Lite Strategy, Inc.NasdaqCM: LITS | $34.97M | $1.15 | -9.45% |
| Holy Stone Healthcare Co., Ltd.TPEX: 4194 | $34.87M | NT$7.75 | -4.32% |
| Biomark Diagnostics Inc.DB: 20B | $34.02M | €0.28 | -4.70% |
| CervoMed Inc.NasdaqCM: CRVO | $33.87M | $2.24 | -30.43% |
| Cell Source, Inc.OTCPK: CLCS | $33.63M | $0.49 | -10.45% |
| Mabion S.A.WSE: MAB | $33.59M | zł8.07 | +0.88% |
Figures last refreshed Oct 18, 2026.